Cleveland Clinic 2004 Medical Innovation Summit In Brief
This article was originally published in The Gray Sheet
Market leader or fast follower?: Guidant's ability to bypass FDA panel review and be first to the U.S. market in August with the Rx Acculink carotid stent suggests an advantage to being a "fast follower," rather than the originator of a brand-new therapy, according to vascular interventionalist Jay Yadav, MD, Cleveland Clinic Foundation. J&J/Cordis' Precise carotid stent withstood panel review and had been widely projected as the first-comer, but still awaits final FDA sign-off. "There is some consternation in the medical device community that it may be more efficient - you may save tens of millions of dollars - by waiting a couple of months and being a fast follower," Yadav claims. "Do we really want an [FDA] environment where true innovation is discouraged for business reasons?"...
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.